Search clinical trials for: Rifaximin Novel Formulation

Total 1780 results

Bausch Health Americas, Inc.

Completed

Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers

Healthy Volunteers

New Zealand
King's College London

Completed

Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation (CLIP)

Absorption; Chemicals

United Kingdom
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Centre Hospitalier Universitaire Saint Pierre

Completed

Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy

Hepatic Encephalopathy

Belgium
University of Roma La Sapienza

Unknown

A RCT COMPARING LACTULOSE AND RIFAXIMIN ASSOCIATED WITH A VEGETABLE DIET IN THE PREVENTION OF POST-TIPS OVERT HEPATIC ENCEPHALOPATHY

Cirrhotic Patients Undergoing TIPS Placement

Italy
Bausch Health Americas, Inc.

Completed

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study (TARGET3)

Irritable Bowel Syndrome With Diarrhea

United States, United Kingdom, Germany
Hillel Yaffe Medical Center

Unknown

Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.

Skin Abnormality

Israel
Bausch Health Americas, Inc.

Completed

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Sickle Cell Disease

United States, Canada, Kenya
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
Bausch Health Americas, Inc.

Completed

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE) (OHE)

Overt Hepatic Encephalopathy

United States
Alfasigma S.p.A.

Terminated

Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. (ROAD)

Diverticulitis

France, Germany, Italy, Netherlands, Spain, United Kingdom
Sandoz

Terminated

A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.

Travelers' Diarrhea

Mexico
National University Hospital, Singapore
National University, Singapore

Completed

Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea

Singapore
Shanghai Changzheng Hospital

Unknown

Rifaximin Predicts the Complications of Decompensated Cirrhosis

Cirrhosis

China
Sun Yat-sen University

Recruiting

The Efficacy and Safety of Rifaximin Treatment

Hepatic Encephalopathy | Hepatitis B | HBV | Effect of Drug | Liver Failure, Acute on Chronic | Rifaximin

China
AstraZeneca

Completed

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

Parkinson's Disease

United Kingdom
Bausch Health Americas, Inc.

Active, not recruiting

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)

Hepatic Encephalopathy

United States, Australia, Canada, Puerto Rico
Mansoura University

Completed

Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic Fatty Liver Disease

Egypt
Xin Zeng

Recruiting

Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis (RPPCLC)

Decompensated Cirrhosis

China
DuPont, Hurbert L., MD
The University of Texas Health Science Center, Houston; Bausch Health Americas...

Completed

Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

Diarrhea

Mexico
Janssen Sciences Ireland UC

Completed

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Healthy

United Kingdom
Institute of Liver and Biliary Sciences, India

Completed

To Compare "Balloon Occluded Thrombolysis" With "Conventional Catheter Directed Thrombolysis" in Thrombotically Occluded DIPSS Stent in Patients of Budd- Chiari Syndrome.

Budd-Chiari Syndrome

India
Alfasigma S.p.A.
Cromsource

Terminated

A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention (STOP-PER)

Crohn Disease

Italy
Johns Hopkins Bloomberg School of Public Health
Naval Medical Research Center; Uniformed Services University of the Health...

Completed

Efficacy of Rifaximin in Preventing Campylobacteriosis

Diarrhea | Dysentery | Enteric Campylobacteriosis

United States
GlaxoSmithKline

Completed

Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Multiple Sclerosis

Poland, Germany, Czechia
Pfizer

Completed

Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers

Healthy

Singapore
Johns Hopkins University
The Thomas Wilson Sanitarium for Children of Baltimore City

Not yet recruiting

Swaddling to Improve Neurodevelopment for Preterm Babies

Preterm Birth | Neurodevelopmental Disorders
David E. Kaplan, MD MSc
Bausch Health Americas, Inc.

Terminated

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Liver Cirrhosis | Chronic Hepatitis C

United States
Bausch Health Americas, Inc.
Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC

Terminated

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Crohn's Disease

United States
Bausch Health Americas, Inc.
Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC

Terminated

One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

Crohn's Disease

United States
Hunter Holmes Mcguire Veteran Affairs Medical Center
Bausch Health Americas, Inc.

Completed

Study of Rifaximin in Minimal Hepatic Encephalopathy

Minimal Hepatic Encephalopathy

United States
Norgine

Completed

Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER) (PROSPER)

Hepatic Encephalopathy

United Kingdom
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Healthy | Gastric Retention

Australia
Alfasigma S.p.A.

Unknown

Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

Papulopustular Rosacea

Italy
Zhongshan Ophthalmic Center, Sun Yat-sen University

Active, not recruiting

Light Emitting Diodes With a Continuous Spectrum of 430-780nm for Myopia Prevention

Eye Diseases | Refractive Errors | Myopia

China
University of Vermont
Healthy Design, LLC

Completed

Novel Arm Restraint in the Intensive Care Unit

Acute Respiratory Failure

United States
Hollister Incorporated

Completed

Wound Fluid Protease Levels During Use of Novel Wound Dressing

Venous Stasis Ulcers

United States
Eugene F Yen, MD

Recruiting

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

Microscopic Colitis

United States
Bausch Health Americas, Inc.

Active, not recruiting

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132)

Hepatic Encephalopathy

United States, Australia, Belgium, Bulgaria, Canada, France, Germany, Hungary, India, Italy, Korea, Republic of, Mongolia, New Zealand, Poland, Puerto Rico, Spain, United Kingdom
Taipei Medical University Shuang Ho Hospital

Unknown

Modulation of Gut Microbiota by Rifaximin in PD Patients

Inflammation | Parkinson Disease

Taiwan
GlaxoSmithKline

Completed

Bioequivalence and Food Effect Study in Healthy Volunteers

Sleep Initiation and Maintenance Disorders

Italy
ViiV Healthcare

Recruiting

A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

HIV Infections

United Kingdom
Bonderup, Ole K., M.D.

Unknown

Rifaximin-treatment of Collagenous Colitis (XiCoCo)

Collagenous Colitis
University of California, San Francisco

Withdrawn

Rifaximin Treatment of Papulopustular Rosacea

Rosacea

United States
Alfasigma S.p.A.

Completed

Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

Crohn's Disease

Israel, Italy, Russian Federation, Poland, Germany, France, Hungary
The Mediterranean Institute for Transplantation...

Not yet recruiting

Graphic Novel for Patients Undergoing EUS-FNB

Stress | Pancreatic Cancer | Anxiety | Pancreatic Cystic Lesions

Italy
University of Massachusetts, Worcester
Brown University

Completed

Testing a Novel Manual Communication System for Mechanically Ventilated ICU Patients

Communication | Ventilation Therapy; Complications

United States
University of North Carolina, Chapel Hill
Bausch Health Americas, Inc.

Not yet recruiting

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

Pouchitis

United States
Taro Pharmaceuticals USA

Completed

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

Pediculosis

United States
China-Japan Friendship Hospital

Not yet recruiting

Novel Wearable Device for Heart Failure Management

Heart Failure

Search clinical trials for: Rifaximin Novel Formulation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations